Psoriasis Prevention Initiative

The PPI, an ambitious research initiative in alignment with NPF's Strategic Plan, aims to identify an intervention that will prevent the onset of psoriatic disease, disease relapse, or relevant comorbidities.

 
Woman working on computer in a lab

The National Psoriasis Foundation (NPF) launched the Psoriasis Prevention Initiative (PPI) grant mechanism in 2020 with the aim to identify an intervention that will prevent the onset of psoriatic disease, disease relapse, or relevant comorbidities. This intervention would overcome many of the obstacles that continue to challenge patients as well as health care providers and significantly improve the lives of those affected by psoriatic disease.

NPF will invest an estimated $6.5 million in PPI grants over the next five years to accomplish these goals.

The first stage of PPI funding aimed to create and support collaborations among clinical researchers, outline a multi-faceted, multi-disciplinary, team-based virtual cluster approach, and explain how this approach will have a high likelihood of identifying an intervention.

The PPI grant program funded three first-year, proof-of-concept proposals in the amount of $250,000 that had the potential to achieve this goal within five years. Grant recipients included Joel Gelfand, M.D., MSCE, Johann Gudjonsson, M.D., Ph.D., and Christopher Ritchlin, M.D.

Awardees underwent a competitive renewal application for subsequent funding in which Joel Gelfand, M.D., MSCE, and the CP3 virtual cluster were selected for subsequent years of funding. Dr. Gelfand’s project, "Prevention of cardiovascular disease and mortality in patients with psoriasis or psoriatic arthritis (CP3): Translating guidelines of care to better outcomes for patients with psoriatic disease", will receive $1,500,000 per year, for years 2 – 5, contingent on satisfactory progress.

Grants not selected for renewal received $1.1 million in subsequent funding from NIH entities based on proof-of-concept data gained during the initial NPF PPI investment.

Joel Gelfand, Psoriasis Prevention Initiative
Prevention of cardiovascular disease and mortality in patients with psoriasis or psoriatic arthritis (CP3): Translating guidelines of care to better outcomes for patients with psoriatic disease
Anatomic representation of a heart

What We Know About Psoriasis and Heart Disease

A deep dive into the progress of the largest single grant investment in the history of NPF.

Read more
Male doctor talks to a female patient in an exam room.

NPF Announces Funding for the Next Phase of the PPI

One project, CP3, led by Joel M. Gelfand, M.D., MSCE., was selected for phase 2 funding after a competitive renewal process.

Read more

Psoriasis Prevention Initiative Sponsors

This activity has been sponsored by educational grants from the following:

AbbvieUCB  logo with slogan 'Inspired by patients. Driven by science.'

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.